According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Eli Lilly remains a top stock to buy and hold. Vertex Pharmaceuticals is moving quickly to expand its markets beyond cystic ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...